drugset
Drugs / PGT121.414.LS
last change Jan 2026 re-read 2 minutes ago

PGT121.414.LS

Monoclonal antibody

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Department of Health and Human Services · HIV Vaccine Trials Network · National Institutes of Health (NIH) · Dale and Betty Bumpers Vaccine Research Center (VRC) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
+3 more · HIV Prevention Trials Network · Monogram Biosciences · National Institute of Mental Health (NIMH)

Trials 8 · a red edge is where a trial was stopped

today NCT06987318 · Ph 1 NCT06517693 · Ph 1 NCT06812494 · Ph 2 NCT06508749 · Ph 1/2 NCT05719441 · Ph 2 NCT05959707 · Ph 1 NCT05184452 · Ph 1 NCT04212091 · Ph 1
20212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT06987318 Dec 2026 → Aug 2027 expected HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting No outcome recorded
Phase 1 NCT06517693 Jan 2026 → Dec 2027 expected — National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 1 NCT05959707 Aug 2024 → Jan 2025 HIV infectious disease HIV Vaccine Trials Network Suspended No outcome recorded
Phase 1 NCT05184452 Nov 2021 → Jul 2023 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT04212091 Nov 2020 → Jan 2023 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT06508749 Nov 2024 → Sep 2027 expected HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 22 trials
Phase 2 NCT06812494 Mar 2025 → Jan 2027 expected HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 2 NCT05719441 Aug 2024 → Apr 2028 expected — National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as PGT121.414.LS ClinicalTrials.gov intervention name — accepted as the source's own label NCT05184452 ↗
7

NCT05719441 ↗

NCT06517693 ↗

NCT04212091 ↗

NCT06812494 ↗

NCT06508749 ↗

NCT05959707 ↗

NCT06987318 ↗
Modality Monoclonal antibody “The aim of this trial was to test the PGT121.414.LS and VRC07-523LS mAbs for safety and pharmacokinetics in adults.” PMID 39667379 ↗ Dec 2024
Route Intravenous “PGT121.414.LS will be administered via IV infusion at 3, 10, or 30 mg/kg (Groups 1-3) or via SC infusion at 5 mg/kg (Group 4).” NCT04212091 ↗
Route Subcutaneous “PGT121.414.LS will be administered via IV infusion at 3, 10, or 30 mg/kg (Groups 1-3) or via SC infusion at 5 mg/kg (Group 4).” NCT04212091 ↗